BMY - AstraZeneca's Cure For Your Ailing Dividend Portfolio: Sustainable Growth
The Rodney Dangerfield effect continues for those leading the commonly shunned big pharma sector. AstraZeneca (AZN) remains the face of this indifference.
In early February of this year, I wrote AstraZeneca Remains An Attractive Total Return Trade In 2020 And Beyond , the second of two articles highlighting the resurgence of some big pharma names (Bristol-Myers Squibb: 2020 Total Return Play With A 2.8% Dividend Yield). Surprisingly, it appears to be the last contributor article written primarily on AZN. No Respect. No Respect.
Truth be told, AstraZeneca just doesn’t seem to